English
简体中文

Company News

Scientific Article

  • Introduction In December 2023, the cardiac surgery team of Guangdong Provincial People's Hospital cooperated with Difei Medical and published a research paper in the journal Clinica Chimica Acta (IF=5.0).The article included 79 patients with left-sided infective endocarditis (LSIE) after valve surgery and conducted a prospective study. The patients' venous blood, arterial blood and valve samples were collected for culture and mNGS detection. The purpose is to explore the detection performance, influencing factors and bacterial flora distribution of mNGS in venous and arterial blood of patients with LSIE, and to provide favorable basis for the clinical application of mNGS.Research background Infective endocarditis (IE) is a disease that occurs on natural or artificial heart valves, endocardial surfaces or
  • In January 2024, Li Fuxiang's team from the Department of Critical Care Medicine of the Western Theater Command General Hospital of the Chinese People's Liberation Army cooperated with Difei Medical and published a rare case report in the journal Frontiers in Cellular and Infection Microbiology (IF=5.7).The patient had necrotizing pneumonia and air cysts caused by Streptomyces albus infection. The strains were identified through whole-genome sequencing (WGS) combined with phylogenetic analysis, and the diagnosis and identification of rare opportunistic pathogens by mNGS technology were explored. ability.
  • In September 2023, the respiratory department team of Xuzhou First People's Hospital cooperated with Difei Medical and published a research paper in the journal BMC Microbiology (IF=4.2).This article performed whole-genome sequencing (WGS) on 18 clinical multidrug-resistant (MDR-Kp) strains of Klebsiella pneumoniae, analyzed their resistance genes and resistance mechanisms, and evaluated the relationship between this study strain and strains in public databases through phylogenetic analysis. sequence homology between.As a co-author, Diffei Medical participated in the data analysis and article writing of this study.

Industry News

  • A few days ago, the Nanjing Science and Technology Bureau announced the 2023 Nanjing Engineering Technology Research Center Certification List.'Nanjing Infection Metagenome Engineering Technology Research Center' built by Difei Medical Technology (Nanjing) Co., Ltd. has been recognized through the procedures of district-level competent department recommendation, expert review, director's office meeting deliberation, and public announcement!
  • The development of modern science and technology promotes medical progress. Metagenomic next-generation sequencing (mNGS) technology has gradually entered the clinic from the laboratory and into the public eye, playing a key role in the diagnosis of many patients with difficult infections .
  • Difei Medical Technology (Nanjing) Co., Ltd. is a star enterprise under Nanjing Shihe Gene Biotechnology Co., Ltd.As a pioneer in the field of pathogenic microorganism detection in China, Difei Medical adheres to the corporate mission of 'born from the sense' and aims at 'innovating technology, transforming medical treatment' to create a more professional and clinically suitable testing product line , Escort the health of the public with advanced medical technology and services.

About Dinfectome

Telephone: + 86 - 4006362325
E-mail: marketing@dinfectome.com
Address: No.128 Huakang Road, Jiangbei New District, Nanjing, Jiangsu Province, China

Follow Us

Copyright© 2023 Difei Medical Technology (Nanjing) Co., Ltd. Su ICP No. 20046744-2 All rights reserved | Sitemap | Privacy Policy | Leadong support